These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8722543)

  • 1. Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration.
    Novelli A; Mazzei T; Meli E; Conti S; Fallani S; Periti P
    J Antimicrob Chemother; 1996 Apr; 37(4):775-81. PubMed ID: 8722543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and urine concentrations of meropenem in ewes.
    Abo El Sooud K
    J Vet Pharmacol Ther; 2004 Feb; 27(1):27-30. PubMed ID: 14995963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
    Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meropenem in subjects with renal insufficiency.
    Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
    Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
    Kelly HC; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():35-41. PubMed ID: 8543497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
    Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
    Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
    Bidgood T; Papich MG
    Am J Vet Res; 2002 Dec; 63(12):1622-8. PubMed ID: 12492274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
    Adnan S; Li JX; Wallis SC; Rudd M; Jarrett P; Paterson DL; Lipman J; Udy AA; Roberts JA
    Int J Antimicrob Agents; 2013 Jul; 42(1):90-3. PubMed ID: 23590897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.
    Jones HK; Kelly HC; Hutchison M; Yates RA; Ross F; Lomax C; Freestone S; Webb D
    Eur J Drug Metab Pharmacokinet; 1997; 22(3):193-9. PubMed ID: 9358198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S
    J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of meropenem in volunteers.
    Bax RP; Bastain W; Featherstone A; Wilkinson DM; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():311-20. PubMed ID: 2808215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in patients with liver disease.
    Thyrum PT; Yeh C; Birmingham B; Lasseter K
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S184-90. PubMed ID: 9126692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.
    Mouton JW; Michel MF
    J Antimicrob Chemother; 1991 Dec; 28(6):911-8. PubMed ID: 1816187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.
    Firsov AA; Mattie H
    Antimicrob Agents Chemother; 1997 Feb; 41(2):352-6. PubMed ID: 9021191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.